All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In chimeric antigen receptor (CAR) therapy, immune cells are taken from the patient, genetically modified to express the CAR construct, and then infused back into the patient. To date, most CAR therapies use engineered T cells, which express the targeted cancer cell antigen. New approaches explore the use of NK cells, allogeneic cell sources, and novel CAR constructs to optimize manufacturing and improve clinical outcomes.